Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biodetection

    UK Government Contracts Abbott to Supply Millions of Coronavirus IgG Lab-Based Antibody Tests

    By Global Biodefense StaffMay 22, 2020
    Share
    Facebook LinkedIn Reddit Email

    Abbott today announced a government contract to supply millions of its laboratory-based IgG antibody tests to National Health Service (NHS) laboratories across the UK over the coming months. The company has already shipped 800,000 antibody tests this week to NHS laboratories, to be used as part of the testing initiative announced by the UK Secretary of State for Health today.

    These tests, alongside the Abbott PCR tests already being used across the NHS, “enable Abbott to support the UK with broad, reliable molecular and antibody testing during this pandemic”, noted Abbott in a statement.

    Abbott’s SARS-CoV-2 IgG test specifically identifies the IgG antibody, which is a protein that the body produces in the late stages of infection and may remain up to months and possibly years after a person has recovered. Abbott designed its test to detect the IgG antibody specifically as it can better help physicians determine recovery from infection, versus looking at a combination of antibodies. Abbott is also developing an IgM antibody test.

    A recent study published in the Journal of Clinical Microbiology found that Abbott’s SARS-CoV-2 IgG antibody test had 99.9% specificity and 100% sensitivity for detecting the IgG antibody in patients 17 days or more after symptoms began.

    Abbott’s IgG antibody test will be available at NHS laboratories across the country, using its ARCHITECT i1000SR and i2000SR and Alinity i laboratory instruments. The ARCHITECT system can run up to 100-200 tests per hour to help hospitals and laboratories with reliable antibody testing during the pandemic.

    “Since this is a new virus, there are still lots of questions. An antibody test provides an important piece of information that will tell if someone has previously been infected and recovered. We will see if a person has antibodies, but we’ll need to learn more to tell us how long they remain and what they mean,” noted Mary Rodgers, Ph.D., Abbott Global Viral Surveillance Program. “A positive test may provide peace of mind that someone has recovered from the illness, but people should still be vigilant about following guidelines.”

    Awards Coronavirus COVID-19 Editor Pick Epidemiology Public Health Emergency Rapid Diagnostics SARS-CoV-2
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleA Replaceable, More Efficient Filter for N95 Masks
    Next Article Large Observational Study Shows No Benefit for Hydroxychloroquine in COVID-19 Patients

    Related Stories

    EPA Developing AMR Risk Framework for Antibacterial and Antifungal Pesticides

    September 29, 2023

    Provide Feedback on Federal DURC Biosafety Oversight of Potential Pandemic Pathogens

    September 24, 2023

    Committee to Examine Transmission and Geographic Spread of Chronic Wasting Disease

    September 24, 2023

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.